RxDoctor Payments Data

Jeff Brown, DO

Family Medicine · Tupelo, MSNPI 1346390093

Payments from drug & device makers

$733in general payments, 2019–2025

Across 36 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$144
  • Nevro Corp.$137
  • Abbott$100
  • Cook Medical LLC$67
  • Novo Nordisk$63
  • Pfizer$47
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$733 in reported general payments places this provider in the 55th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$151,043
Medicare patients
537
Services billed
5,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$24,283
MounjaroTirzepatide12$16,450
Losartan Potassium77$862
Rosuvastatin Calcium97$836
Gabapentin60$830
Duloxetine Hcl36$811
Celecoxib41$755
Betamethasone Dipropionate19$694
Diclofenac Sodium36$684
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen91$649
Atorvastatin Calcium67$632
Doxycycline Monohydrate68$536
Omeprazole46$459
Pregabalin16$452
Levothyroxine Sodium62$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$63$24,28311 claims
Lilly USA, LLCMounjaro$144$16,45012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →